Synthesis of an oligosaccharide–polylysine dendrimer with reducing sugar terminals leading to acquired immunodeficiency syndrome vaccine preparation

A novel cellobiose–polylysine dendrimer with reducing sugar terminals was synthesized in which the reactive reducing end of a disaccharide cellobiose was directing outward. Hexa‐O‐benzyl‐4′‐(1‐carboxyethyl)‐cellobioside (HBCEC) was synthesized through the reaction of a 4′‐hydroxyl group of benzyl hexa‐O‐benzyl‐cellobioside with methyl 2‐chloropropionate, followed by the removal of the methyl ester group. HBCEC was reacted with polylysine dendrimer generation 3 (G3) to produce benzylated cellobiose–polylysine dendrimer G3. After debenzylation, a cellobiose–polylysine dendrimer G3 was obtained in which the reducing end of the cellobiose was the terminal group of the dendrimer. For the preparation of a dendrimer‐type acquired immunodeficiency syndrome vaccine, the cellobiose–polylysine dendrimer was reacted with a tripeptide (glycyl–prolyl–leucine) and a cyclic oligopeptide from the human immunodeficiency virus by reductive amination; this produced a tripeptide‐bound cellobiose–polylysine dendrimer and an insoluble compound, respectively. The structure analysis was carried out with NMR and matrix‐assisted laser desorption/ionization time‐of‐flight mass spectrometry.